Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2018
Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City. Dan Brennan, executive vice president and chief...
-
Nov 6, 2018
Boston Scientific Corporation (NYSE: BSX) will participate in the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, Arizona. Joe Fitzgerald, executive...
-
Oct 24, 2018
"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.
-
Oct 23, 2018Court Rules Edwards Lifesciences' Next-Generation Valve Infringes Boston Scientific Patent and Grants Right to Enjoin Sales in Germany
Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.
-
Oct 16, 2018
The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.
-
Oct 10, 2018Data Support Minimally Invasive Single-Incision Mesh Procedure as a Durable, Safe and Effective Treatment for Stress Urinary Incontinence, a Condition that Affects 18 Million American Adults
Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.
-
Oct 1, 2018Fourth annual Connected Patient Challenge focuses on utilizing population health data, patient monitoring or predictive analytics to improve patient care and lower healthcare costs
4th annual Connected Patient Challenge focuses on using population health data, patient monitoring or predictive analytics to improve care and lower costs.
-
Oct 1, 2018
Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2018. Learn how to tune in.
-
Sep 24, 2018First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease
Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.
-
Sep 22, 2018First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries
First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.